Johnson & Johnson said Monday that its drug Remicade met key goals in treating pediatric patients with moderate to severe ulcerative colitis in a late-stage study.
Ulcerative colitis is a chronic inflammatory bowel disease affecting nearly 700,000 people in the U.S. Remicade is already approved as a treatment for adults with ulcerative colitis and is under review by the Food and Drug Administration for the pediatric indication.
The drug is also approved to treat autoimmune disorders including rheumatoid arthritis, plaque psoriasis and Crohn's disease.
In the study, Remicade prompted a response in 73 percent of patients between the ages of 6 years and 17 years after eight weeks. The study involved 60 patients with moderate to severe ulcerative colitis.
Shares of Johnson & Johnson rose 36 cents to close at $65.63.